Organoids that responded well to LY2584702 combined with either alpelisib or capivasertib were derived either from patients with no clinically actionable CRC-related mutations or from patients with both KRAS and PIK3CA mutations. The gene discussed is KRAS; the disease is colorectal carcinoma.